• Anal Cancer 
• Cholangiocarcinoma 
• Colon Cancer
• Esophageal Cancer 
• Gastric Cancer
• Hepatocellular Carcinoma
• Neuroendocrine Tumors
• Pancreatic Cancer
• Rectal Cancer

Fellowships

• University of Miami - Jackson Hospital - Oncology and Hematology Fellowship, 2015, Oncology and Hematology

Residency

• University of Miami - Jackson Memorial Hospital - Internal Medicine Prog, 2012, Internal Medicine

Internships

• University of Miami - Jackson Memorial Hospital - Internal Medicine Prog, 2012, Internal Medicine

Medical Education

• Harvard T.H. Chan-School of Public Health, 2021
• Universidad Del Norte Programa De Medicina, 2003

Certifications

• American Board of Internal Medicine-Hematology
• American Board of Internal Medicine-Internal Medicine
• American Board of Internal Medicine-Medical Oncology

Publications

Please view Dr. Jesus C. Fabregas publications on PubMed.

Research

My research endeavors included a meta-analysis studying the feasibility of minimizing toxicities in patients with early rectal cancer, and refining prognosis and treatment selection for patients with early colon cancer applying a machine-learning model.

Recenter research projects where I served as local principal investigator include:

• 2022 – NCT05174169 Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)
  
  
• 2019 - NCT03703297 Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
  
  
• 2019 - NCT03829332 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1%(LEAP-007)
  
  
• 2019 - NCT03294083 A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase Deactivated Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti-PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)
  
  
• 2019 - NCT03448978 Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients with Multiple Myeloma
  
  
• 2018 - NCT03452137 A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
  
  
• 2018 - NCT03033511 A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First Line Platinum Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
  
  
• 2018 - NCT03365791 PDR 001 Plus LAG525 For Patients with Advanced Solid and Hematologic Malignancies

Professional Organizations

• American Society of Clinical Oncology (ASCO)
• American College of Physicians (ACP)
• Florida Society of Clinical Oncology (FLASCO)
• NRG Oncology

Presentations

• Importance Order of Risk Factors for Mortality in Colon Cancer Stage II: A Multivariate Adaptive Regression Spline (MARS) Analysis, Annals of Oncology Volume 32, supplement 3, 2021. Oral virtual presentation at ESMO GI World Congress 2021. Barcelona, Spain.
  
  
• Sherise C. Rogers, Shu Wang, Ryan Michael Thomas, Brian Hemendra Ramnaraign, Jesus C. Fabregas, Ilyas Sahin, Stephen Staal, Martina Cathryn Murphy, Anna Melissa Singson Murillo, Merry Jennifer Markham, Frederic J. Kaye, Coy D. Heldermon, Dennie V. Jones, Nam H. Dang, Julia Lee Close, Thomas J. George, Carmen Joseph Allegra. A phase II randomized therapeutic optimization trial for subjects with refractory metastatic colorectal cancer using circulating tumor DNA (ctDNA): Rapid 1 trial. Poster presentation ASCO GI. San Francisco. January 2022.
  
  
• Thomas J. George, Greg Yothers, Samuel A. Jacobs, Gene Grant Finley, James Lloyd Wade, Caio Max Sao Pedro Rocha Lima, Jeffrey Scott Rose, Shalu Pahuja, Anuradha Krishnamurthy, John C. Krauss, Melvin Deutsch, Jesus C. Fabregas, James J. Lee, Carmen Joseph Allegra, Norman Wolmark. Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2. Poster presentation ASCO GI. San Francisco. January 2022.
  
  
• Brian Hemendra Ramnaraign, Ji-Hyun Lee, azka ali, Sherise C. Rogers, Jesus C. Fabregas, Ryan M. Thomas, Carmen Joseph Allegra, Ilyas Sahin, David L. DeRemer, Thomas J. George, Jonathan Alexander Chatzkel. A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder and biliary cancers. Poster presentation ASCO GI. San Francisco. January 2022.
  
  
• Sherise C. Rogers, Ji-Hyun Lee, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Anita Ahmed Turk, Karen Bullock Russell, Ahmad El-Far, Ryan M. Thomas, Jesus C. Fabregas, Ilyas Sahin, Carmen Joseph Allegra, David L. DeRemer, Thomas J. George. A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study. Poster presentation ASCO GI. San Francisco. January 2022.

Awards

• 2015 Peter A. Cassileth, M.D. Award University of Miami Miller School of Medicine Division of Hematology Oncology, Presented to a Fellow with Outstanding Clinical Judgement and Compassion Miami, FL.
• 2014 American Society of Hematology Advocacy Leadership Institute Elected to represent ASH in advocacy efforts at the Congress in Washington, DC.
• 2012 American College of Physicians (ACP) Outstanding Resident Award University of Miami – American College of Physicians Miami, FL.
• 2011 National Winner – Poster Presentation ACP Internal Medicine Meeting San Diego, CA. 2010 1st Place ACP Scientific Meeting, Oral Presentation Fort Lauderdale, FL.